Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vericiguat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 known ✓ | Q02108 | 2/20 | 0.54 |
| ▸ | GUCY1B1 known ✓ | Q02153 | 2/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | PDE5A | O76074 | 17/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vericiguat SCHEMBL30277583 | 1.00 | ADORA3 (0.56) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL29379616 | 0.99 | ADORA3 (0.57) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL29382575 | 0.99 | ADORA3 (0.57) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL30395636 | 0.99 | ADORA3 (0.57) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL429958 | 0.99 | ADORA3 (0.57) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL29906114 | 0.96 | ADORA3 (0.54) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL29906109 | 0.96 | ADORA3 (0.54) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL29906117 | 0.96 | ADORA3 (0.54) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL29906094 | 0.94 | GUCY1A1 (0.53) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL29906089 | 0.94 | ADORA3 (0.53) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11439642-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2022-09-13 | — | — | US | claimed |
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2022-12-29 | — | — | US | disclosed |
| US-11439642-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2022-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | GUCY1A1 1337/4885GUCY1B1 1025/4885ADORA3 1633/4885 |
| US-11439642-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | GUCY1A1 1337/4885GUCY1B1 1025/4885ADORA3 1633/4885 |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | GUCY1A1 1337/4885GUCY1B1 1025/4885ADORA3 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.